Henryk Mach

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. doi request reprint Ultraviolet spectroscopy as a tool in therapeutic protein development
    Henryk Mach
    Merck Research Laboratories, WP78 302, West Point, Pennsylvania
    J Pharm Sci 100:1214-27. 2011
  2. doi request reprint The use of flow cytometry for the detection of subvisible particles in therapeutic protein formulations
    Henryk Mach
    Merck Research Laboratories, Bioprocess Analytical and Formulation Sciences, West Point, Pennsylvania 19486, USA
    J Pharm Sci 100:1671-8. 2011
  3. doi request reprint Addressing new analytical challenges in protein formulation development
    Henryk Mach
    Merck Research Laboratories, Merck and Co, West Point, USA
    Eur J Pharm Biopharm 78:196-207. 2011
  4. ncbi request reprint Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
    John W Shiver
    Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    Nature 415:331-5. 2002
  5. pmc Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene
    Danilo R Casimiro
    Department of Viral Vaccine Research, Merck and Company, West Point, Pennsylvania 19486, USA
    J Virol 77:6305-13. 2003
  6. pmc Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene
    Danilo R Casimiro
    Department of Viral Vaccine Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    J Virol 77:7663-8. 2003
  7. ncbi request reprint Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs)
    Henryk Mach
    Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    J Pharm Sci 95:2195-206. 2006
  8. ncbi request reprint Characterization and biological evaluation of a microparticle adjuvant formulation for plasmid DNA vaccines
    Robert K Evans
    Department of Vaccine Pharmaceutical Research, Merck Research Laboratories, WP78 302, Sumneytown Pike, West Point, Pennsylvania 19486, USA
    J Pharm Sci 93:1924-39. 2004
  9. doi request reprint High throughput formulation screening for global aggregation behaviors of three monoclonal antibodies
    Yi Li
    Vaccine and Biologics Process Development, Merck and Corporation, Inc, West Point, Pennsylvania 19486, USA
    J Pharm Sci 100:2120-35. 2011

Detail Information

Publications9

  1. doi request reprint Ultraviolet spectroscopy as a tool in therapeutic protein development
    Henryk Mach
    Merck Research Laboratories, WP78 302, West Point, Pennsylvania
    J Pharm Sci 100:1214-27. 2011
    ..2010 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 100:1214-1227, 2011. ..
  2. doi request reprint The use of flow cytometry for the detection of subvisible particles in therapeutic protein formulations
    Henryk Mach
    Merck Research Laboratories, Bioprocess Analytical and Formulation Sciences, West Point, Pennsylvania 19486, USA
    J Pharm Sci 100:1671-8. 2011
    ..The method is expected to be particularly well suited for pharmaceutical development, because it provides increased throughput due to the use of a 96-well autosampler...
  3. doi request reprint Addressing new analytical challenges in protein formulation development
    Henryk Mach
    Merck Research Laboratories, Merck and Co, West Point, USA
    Eur J Pharm Biopharm 78:196-207. 2011
    ..Most of these approaches allow not only a more precise insight into the nature of the formulated proteins, but also offer increased throughput while minimizing sample requirements...
  4. ncbi request reprint Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
    John W Shiver
    Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    Nature 415:331-5. 2002
    ..The replication-defective adenovirus is a promising vaccine vector for development of an HIV-1 vaccine...
  5. pmc Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene
    Danilo R Casimiro
    Department of Viral Vaccine Research, Merck and Company, West Point, Pennsylvania 19486, USA
    J Virol 77:6305-13. 2003
    ....
  6. pmc Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene
    Danilo R Casimiro
    Department of Viral Vaccine Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    J Virol 77:7663-8. 2003
    ..The implications of these results are discussed...
  7. ncbi request reprint Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs)
    Henryk Mach
    Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    J Pharm Sci 95:2195-206. 2006
    ..This development illustrates how the natural, in vivo mechanisms facilitating cell entry and virus replication can be utilized to achieve an optimal, in vitro assembly state of yeast-expressed HPV VLPs...
  8. ncbi request reprint Characterization and biological evaluation of a microparticle adjuvant formulation for plasmid DNA vaccines
    Robert K Evans
    Department of Vaccine Pharmaceutical Research, Merck Research Laboratories, WP78 302, Sumneytown Pike, West Point, Pennsylvania 19486, USA
    J Pharm Sci 93:1924-39. 2004
    ..These results indicate that the addition of BAK to DNA/CRL1005 formulations leads to the formation of approximately 300 nm CRL1005-BAK-DNA particles that enhance the cellular immune response in rhesus monkeys...
  9. doi request reprint High throughput formulation screening for global aggregation behaviors of three monoclonal antibodies
    Yi Li
    Vaccine and Biologics Process Development, Merck and Corporation, Inc, West Point, Pennsylvania 19486, USA
    J Pharm Sci 100:2120-35. 2011
    ..Understanding global aggregation behaviors is a key element toward development of rational screening approach...